Adjusted vs Reported EPS: Which One Should a Dividend Investor Use?

AstraZeneca earned $6.60 a share in 2025. It also earned $9.16 a share. Both figures appear in the company's full-year results, for the same year and the same shares. The first is reported earnings per share, the figure the accounting rules produce. The second is what AstraZeneca calls Core EPS, its own adjusted version. It is also the figure the company's guidance for 2026 is expressed in.

The dividend for 2025 was $3.20 a share. It sits below both figures, but by very different margins. In 2021 the difference was far starker: reported earnings were $0.08 a share, core earnings $5.29, and the dividend $2.87. Read one figure and earnings covered almost none of the dividend. Read the other and it was comfortably covered.

Both readings come from the same company's own results. The question for a dividend investor is which one to believe, and the answer is neither, on its own.

What is the difference between reported and adjusted EPS?

Reported EPS is net profit attributable to shareholders, divided by the average number of shares in issue. It follows the accounting standards, IFRS in AstraZeneca's case, and it sits inside the audited accounts.

Adjusted EPS starts from the same profit and removes items the company treats as outside its ongoing performance. No accounting standard defines it, so each company sets its own list and picks its own name: adjusted, non-GAAP, core, underlying, or "headline" earnings. If two sites quote different earnings for the same company, both can be right, for much the same reason that dividend growth figures disagree between sites.

AstraZeneca prints the bridge between its two figures in the results release itself:

Almost the whole gap is one line. Amortisation and impairment of intangible assets added $2.26 a share, against $0.11 for restructuring and $0.19 for other items. The company describes those other items as mainly acquisition-related costs and credits, plus legal settlements.

Where does the gap come from?

When AstraZeneca buys another company, it records the value of the medicines and rights it acquired as intangible assets on its balance sheet. It then writes that value down over the years those rights are expected to earn money. The write-down is amortisation, and it reduces reported profit every year.

No cash leaves the business when amortisation is booked. The cash went out once, when the company paid for the acquisition. That is the argument for setting it aside: it describes a purchase made in the past, not the cost of running the business today.

The counter-argument is just as simple. Every acquisition was paid for, in cash or in new shares, with value that belonged to shareholders. Amortisation is how the accounts spread that price over the years the acquired assets earn. Leave it out every year, and the earnings include the sales and profits of the businesses bought while never carrying what was paid for them.

The 2021 low point has a named cause. In its 2021 results, the company said the differences between its reported and core measures were "primarily due to items related to the acquisition of Alexion". That was the year reported earnings fell to $0.08 a share.

Is the gap a one-off?

A core measure is meant to set aside items that distort a single year. AstraZeneca's five most recent years show what happens in practice.

Sources: AstraZeneca full-year results for 2021, 2022, 2023, 2024 and 2025. Reported EPS is the basic figure.

Core EPS was above reported EPS in every one of the five years. The gap has narrowed as reported earnings have grown faster, but it has never closed. Amortisation is not a single-year item. It comes back every year until the acquired rights are fully written down, and each new acquisition adds a charge of its own.

The dividend column makes the point sharper. In 2021 and 2022, reported earnings of $0.08 and $2.12 a share did not cover dividends of $2.87 and $2.90. On core earnings, the dividend was covered in every year. A screen that flags any dividend larger than reported earnings would have caught AstraZeneca twice in five years. Run on core earnings, it would never have caught it.

Which figure should a dividend investor use?

The case for the reported figure is that it is audited, follows one standard, and does not let the company choose what to leave out. It also includes costs that do consume cash. Restructuring charges and legal settlements are mostly paid in cash, and a company that restructures every year is not having a one-off.

The case for AstraZeneca's core figure is that most of its gap is amortisation, which consumes no cash. A dividend is paid in cash. Measured against reported earnings, a company with large acquired intangibles looks more stretched than it is. AbbVie is the extreme example of the same mechanism, covered in our guide to payout ratios over 100%.

Neither figure settles the question by itself. The test that does is whether free cash flow covers the dividend. If it does, the gap between the two EPS figures is mostly accounting. If it does not, a generous core figure is not a reason to relax.

Is AstraZeneca unusual?

Not in direction. We lined up the two figures for 1,249 US companies over their last ten complete financial years. We used US companies because their earnings data is on the adjusted basis by convention, so each company could be measured whether or not its two figures agree. For European companies the published basis varies, and measuring only those with a visible gap would overstate it.

At the median company, the two figures sat 14.6% apart in a typical year, measured as a share of the larger figure. For 42% of companies the usual gap was more than 20%. The direction is the striking part: in the 9,663 company-years where the two figures differed by more than 2%, the adjusted figure was the higher one 78.5% of the time. If adjustments removed only genuine one-offs, gains and costs would roughly balance. They do not, so most of what gets removed is a recurring cost.

The gap is widest in technology, with a median of 30.2%, and in healthcare at 25.1%. It is narrowest at utilities (4.7%) and financial companies (7.4%). It also reaches the dividend. Among the US companies that paid one, 140 had reported earnings that did not cover the dividend in their latest complete year. On the company's adjusted figure, 94 of them were covered.

Which figure does the Dividend Health Score use?

The Dividend Health Score uses reported earnings, measured over several complete financial years. The figure is audited, it follows one standard, and the company does not choose what to leave out.

AstraZeneca shows the cost of that choice: a non-cash charge makes a company look more stretched than it is. That is why the score reads free cash flow coverage beside the earnings payout ratio, rather than relying on either one. In the app, a stock's Financials tab shows both EPS figures, with a switch between them, wherever the two can be lined up year by year.

Where do European companies publish the two figures?

European companies use their own names for the adjusted figure: underlying, core, recurring or "clean" earnings. The European Securities and Markets Authority's guidelines on alternative performance measures require a company to define each one and reconcile it to the nearest IFRS figure.

In practice, that reconciliation sits in the results release or the annual report, usually in a section on alternative performance measures. AstraZeneca's is a table with one column per adjustment and a written definition of each item. For this question it is the most useful page in the report.

The same choice shapes dividend targets. Almost half of the European payout policies we hold set their target on an adjusted figure, as what European companies actually promise sets out.

How should you read the two figures?

• Find the reconciliation. It lists every item between the two figures, with an amount for each. Read the list before you read either total.
• Look at several years, not one. One year's gap describes that year. An adjusted figure above the reported one in most years means the excluded item is a running cost.
• Ask whether the excluded item is paid in cash. Amortisation of an acquired asset is not. Restructuring costs and legal settlements usually are.
• Match the payout ratio to its basis. A payout target set on adjusted earnings is not comparable with a payout ratio on reported earnings, including ours.
• Then check the cash. If free cash flow covers the dividend, the choice of EPS matters less. If it does not, neither EPS figure rescues the dividend.

The same habit of asking which figure you are looking at applies to dividend data too. Our guide to checking a dividend figure sets out the five questions worth asking before you rely on one.